EHD2 and breast cancer: Given the predominantly cytoplasmic/membrane localization of EHD2 in the mammary gland and BC cell lines, but the reported nuclear localization in cell lines under defined conditions (Torrino et al., 2018; Pekar et al., 2012), we quantified the IHC signals as cytoplasmic and nuclear (Figure 3A).